Real-world durability of effectiveness through 24 months of anti-interleukin (IL)-17A biologics and other approved biologics in treating patients with moderate-to-severe psoriasis in PSoHO
Por:
Tjioe, M, Costanzo, A, Carrascosa, JM, Bovenschen, HJ, Maul, JT, de Hoog, N, Martimianaki, G, Lampropoulou, A, McKenzie, R, Pinter, A and Daniel, B
Publicada:
1 jun 2025
Resumen:
Filiaciones:
Tjioe, M:
Bravis Hosp, DermaTeam Res, Roosendaal, Netherlands
Costanzo, A:
Humanitas Univ, Milan, Italy
:
Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Barcelona, Spain
Bovenschen, HJ:
Maxima Med Ctr Veldhoven, Veldhoven, Netherlands
Maul, JT:
Univ Hosp Zurich, Zurich, Switzerland
de Hoog, N:
Eli Lilly & Co, Indianapolis, IN USA
Martimianaki, G:
Eli Lilly & Co, Indianapolis, IN USA
Lampropoulou, A:
Eli Lilly & Co, Indianapolis, IN USA
McKenzie, R:
Eli Lilly & Co, Indianapolis, IN USA
Pinter, A:
Univ Zurich, Zurich, Switzerland
Univ Hosp Frankfurt, Frankfurt, Germany
Daniel, B:
St Vincents Hosp Melbourne, Melbourne, Australia
|